---
title: "688428.SH (688428.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688428.SH/news.md"
symbol: "688428.SH"
name: "688428.SH"
parent: "https://longbridge.com/en/quote/688428.SH.md"
datetime: "2026-05-20T18:48:26.906Z"
locales:
  - [en](https://longbridge.com/en/quote/688428.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688428.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688428.SH/news.md)
---

# 688428.SH (688428.SH) — Related News

### [InnoCare Pharma CEO Cui Jisong: R&D, commercialization, and globalization running in parallel | 21 Health Talk](https://longbridge.com/en/news/287017731.md)
*2026-05-20T06:29:12.000Z*
> In the first quarter of 2026, InnoCare Pharma achieved revenue of 529 million yuan, a year-on-year increase of 38.65%, a

### [InnoCare Pharma: New TYK2 inhibitor ICP-488 completes first patient enrollment in Phase II clinical trial for CLE](https://longbridge.com/en/news/286838297.md)
*2026-05-19T01:34:15.000Z*
> On May 19th, InnoCare Pharma announced that the first patient enrollment for the Phase II clinical trial of its self-dev

### [Insight into the Q1 2026 Report of STAR Market Pharmaceutical Companies: Profit Breakthrough, Reshaping the Game](https://longbridge.com/en/news/286580848.md)
*2026-05-15T06:04:13.000Z*
> In the first quarter of 2026, the financial data of biotechnology and pharmaceutical companies on the STAR Market was im

### [InnoCare Pharma's potential treatment for autoimmune diseases has entered clinical trials, with the first subject enrolled](https://longbridge.com/en/news/286336066.md)
*2026-05-14T00:50:00.000Z*
> InnoCare Pharma announced that the Phase 1 clinical trial of its novel oral IL-17AA/AF inhibitor ICP-054 has completed t

### [InnoCare Pharma: The first subject has been enrolled in the Phase 1 clinical trial of ICP-054 (ZB021)](https://longbridge.com/en/news/286245297.md)
*2026-05-13T10:51:59.000Z*
> InnoCare Pharma announced that the first subject has been enrolled in the Phase 1 clinical trial of its novel oral IL-17

### [InnoCare Pharma's new TYK2 inhibitor ICP-488 for the treatment of Sjögren's syndrome has been approved by the CDE for Phase II clinical trials](https://longbridge.com/en/news/285644512.md)
*2026-05-08T01:11:24.000Z*
> On May 8th, InnoCare Pharma announced that its self-developed novel TYK2 inhibitor for the treatment of Sjögren's syndro

### [Overview of IPO cornerstone investors' upcoming lock-up expiration](https://longbridge.com/en/news/285640382.md)
*2026-05-08T00:20:00.000Z*
> The cornerstone investors of the IPO will have their lock-up period lifted on May 10 and May 15, 2026, involving the num

### [InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China](https://longbridge.com/en/news/285473001.md)
*2026-05-07T02:25:00.000Z*
> InnoCare Pharma has received approval from the China National Medical Products Administration to initiate a clinical tri